European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
March 26, 2019 6:27 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.
ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... MoreBaird Incrementally Positive on Aimmune Therapeutics (AIMT) ARTEMIS Topline Readout
March 25, 2019 12:52 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) saying they are incrementally positive on ARTEMIS topline readout.
Skorney commented, "Aimmune announced today that the Phase 3 European trial of AR101 met its primary endpoint,... More
